Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial

By sjmartinez • May 7, 2023

Tags: combination therapy, durvalumab, Hematology/Oncology, immunotherapy, Non-small cell lung cancer, Publications, tremelimumab

Screening for frailty and malnutrition in a multidisciplinary head and neck cancer program

Brauer ER, Lazaro S, Economou DR, Rapkin D, Wong DJ, St John MA. Screening for frailty and malnutrition in a multidisciplinary head and neck cancer[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen[...]